Detects human VEGFR2/KDR/Flk-1 in direct ELISAs. In direct ELISAs, no cross-reactivity with recombinant human (rh) VEGFR1, rhVEGFR3 or recombinant mouse VEGFR2 is observed.

Clonality

Monoclonal

Host

Mouse

Isotype

IgG₁

Endotoxin Level

<0.10 EU per 1 μg of the antibody by the LAL method.

Scientific Data Images for Human VEGFR2/KDR/Flk-1 Antibody

Detection of VEGFR2/KDR/Flk‑1 in HUVEC Human Cells by Flow Cytometry.

HUVEC human umbilical vein endothelial cells were stained with Mouse Anti-Human VEGFR2/KDR/Flk-1 Monoclonal Antibody (Catalog # MAB3572, filled histogram) or isotype control antibody (Catalog # MAB002, open histogram), followed by Phycoerythrin-conjugated Anti-Mouse IgG Secondary Antibody (Catalog # F0102B).

VEGFR2/KDR Inhibition of VEGF-dependent Cell Proliferation and Neutralization by Human VEGFR2/KDR Antibody.

Recombinant Human VEGFR2/KDR Fc Chimera (Catalog # 357-KD) inhibits Recombinant Human VEGF₁₆₅(Catalog # 293-VE) induced proliferation in HUVEC human umbilical vein endothelial cells in a dose-dependent manner (orange line). Inhibition of Recombinant Human VEGF₁₆₅(10 ng/mL) activity elicited by Recombinant Human VEGFR2/KDR Fc Chimera (50 ng/mL) is neutralized (green line) by increasing concentrations of Mouse Anti-Human VEGFR2/KDR Monoclonal Antibody (Catalog # MAB3572). The ND₅₀ is typically 10-50 ng/mL.

Detection of VEGFR2/KDR/Flk-1 by Flow Cytometry

Induction of endothelial markers in circulating CD14+ cells. CD14+ monocytes were isolated from adult PB, cultured in EGM-2 MV with or without MSCs, and then analyzed with flow cytometry. Dot plots from freshly isolated CD14+ cells (A) and after 4 days of co-culture with adipose-derived MSCs (green) (B) are shown. Flow-cytometry histograms in panels A and B show the expression of KDR and Tie2 in gated CD14+ cells. Isotype-matched controls are given. Image collected and cropped by CiteAb from the following open publication (https://pubmed.ncbi.nlm.nih.gov/24731246), licensed under a CC-BY license. Not internally tested by R&D Systems.

Applications for Human VEGFR2/KDR/Flk-1 Antibody

Application

Recommended Usage

CyTOF-ready

Ready to be labeled using established conjugation methods. No BSA or other carrier proteins that could interfere with conjugation.

Flow Cytometry

0.25 µg/10⁶ cells
Sample: HUVEC human umbilical vein endothelial cells

Neutralization

Measured by its ability to neutralize VEGFR2/KDR/Flk‑1-mediated inhibition of proliferation in HUVEC human umbilical vein endothelial cells. The Neutralization Dose (ND₅₀) is typically 10-50 ng/mL in the presence of 50 ng/mL Recombinant Human VEGFR2/KDR/Flk‑1 Fc Chimera and 10 ng/mL Recombinant Human VEGF₁₆₅.

Reviewed Applications

Read 2 reviews rated 5 using MAB3572 in the following applications:

ELISA (1 Review)
Flow Cytometry (1 Review)

Formulation, Preparation, and Storage

Purification

Protein A or G purified from hybridoma culture supernatant

Reconstitution

Reconstitute at 0.5 mg/mL in sterile PBS. For liquid material, refer to CoA for concentration.

Formulation

Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose. *Small pack size (SP) is supplied either lyophilized or as a 0.2 µm filtered solution in PBS.

Shipping

Lyophilized product is shipped at ambient temperature. Liquid small pack size (-SP) is shipped with polar packs. Upon receipt, store immediately at the temperature recommended below.

Stability & Storage

Use a manual defrost freezer and avoid repeated freeze-thaw cycles.

12 months from date of receipt, -20 to -70 °C as supplied.
1 month, 2 to 8 °C under sterile conditions after reconstitution.
6 months, -20 to -70 °C under sterile conditions after reconstitution.

Background: VEGFR2/KDR/Flk-1

VEGFR2 (KDR/Flk-1), VEGFR1 (Flt-1) and VEGFR3 (Flt-4) belong to the class III subfamily of receptor tyrosine kinases (RTKs). All three receptors contain seven immunoglobulin-like repeats in their extracellular domains and kinase insert domains in their intracellular regions. The expression of VEGFR1, 2, and 3 is almost exclusively restricted to the endothelial cells. These receptors are likely to play essential roles in vasculogenesis and angiogenesis. Mature VEGFR2 is composed of a 745 aa extracellular domain, a 25 aa transmembrane domain and a 567 aa cytoplasmic domain. In contrast to VEGFR1 which binds both PlGF and VEGF with high affinity, VEGFR2 binds VEGF but not PlGF with high affinity. The recombinant soluble VEGFR2/Fc chimera binds VEGF with high affinity and is a potent VEGF antagonist.

References

Ferra, N. and R. Davis-Smyth (1997) Endocrine Reviews 18:4.

Long Name

Vascular Endothelial Growth Factor Receptor 2

Alternate Names

CD309, Flk-1, Flk1, KDR, KRD1, Ly73, VEGF R2

Entrez Gene IDs

3791 (Human); 16542 (Mouse)

Gene Symbol

KDR

UniProt

P35968

Additional VEGFR2/KDR/Flk-1 Products

Product Documents for Human VEGFR2/KDR/Flk-1 Antibody

Product Datasheets

Download Product Datasheets

COA

SDS

Download SDS

Product Specific Notices for Human VEGFR2/KDR/Flk-1 Antibody

For research use only

Citations
Reviews

Calculators
Flow Cytometry

Human VEGFR2/KDR/Flk-1 Antibody

R&D Systems, part of Bio-Techne | Catalog # MAB3572

Key Product Details

Species Reactivity

Validated:

Cited:

Applications